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ity-adjusted life-years (QALYs), was calculated for patients receiving ADAMTX,
IFXMTX, and MTX alone. Outcomes were examined separately for MTX-naïve and
disease-modifying antirheumatic drug (DMARD)–failure patients. Treatment ben-
efits were measured by American College of Rheumatology 20, 50, and 70 responses
and translated into improvements in Health Assessment Questionnaire Disability
Index scores. Risks comprised loss of drug efficacy and adverse events; patients
could withdraw from treatment due to either. Benefits and risks were associated
with increments and decrements in QALYs, respectively. Data were derived from
the published literature and drug prescribing information. RESULTS: MTX-naïve
patients on ADAMTX, IFXMTX, and MTX alone withdrew after 3.31, 2.46, and
2.71 years and accrued NHBs of 1.40, 1.05, and 1.08 QALYs, respectively. Thus,
MTX-naïve patients on ADAMTX accrued incremental NHBs of 0.35 (P  .05) ver-
sus IFXMTX and 0.32 (P  .05) versus MTX alone. DMARD-failure patients on
ADAMTX, IFXMTX, and MTX alone withdrew after 3.33, 2.11, and 1.44 years and
accrued NHBs of 1.38, 0.86, and 0.57 QALYs, respectively. Thus, DMARD-failure
patients on ADAMTX incurred incremental NHBs of 0.51 (P .05) versus IFXMTX
and 0.81 (P  .05) versus MTX alone. CONCLUSIONS: Understanding the benefit-
risk tradeoff is important for clinicians when prescribing anti-TNFs. Both MTX-
naïve and DMARD-failure patients may experience greater NHB when treated with
ADAMTX than when treated with IFXMTX or MTX alone.
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The GO-REVEAL clinical trial has shown golimumab to be effective in the treatment
of active and progressive PsA. A recently published article by Yang et al. that cov-
ered the NICE technology appraisal process for psoriatic arthritis (TA220) presented
an indirect comparison that suggested differences in treatment effects between
different anti-Tumor Necrosis Factor-ainhibitors (TNFs). OBJECTIVES: To evaluate
the comparative efficacy of anti-TNF drugs for the treatment of PsA in patients with
an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) us-
ing a a critical appraisal of the Yang et al. manuscript and network meta-analysis.
METHODS: The previous indirect comparison was analysed, identified errors cor-
rected, and assumptions altered where necessary. A network meta-analysis was
then performed based on these updated parameters. Indirect comparisons were
performed for the available anti-TNFs (adalimumab, etanercept, golimumab, and
infliximab) measuring relative risks for the PsA response criteria (PsARC), mean
differences for improvements from baseline for the Health Assessment Question-
naire (HAQ) by PsARC responders and non-responders, and mean difference for the
improvements from baseline for the psoriasis area and severity index (PASI). When
the reporting of data on intervention group response rates and improvements were
incomplete, straightforward conversions were used, based on the available data.
RESULTS: All anti-TNFs were significantly better than control. The indirect com-
parison did not reveal any statistically significant difference between the anti-TNFs
using the updated parameters. CONCLUSIONS: There is insufficient statistical ev-
idence to demonstrate differences in efficacy between available anti-TNFs for PsA.
Estimates of effect appear to be sensitive to the analytic approach, so this uncer-
tainly should be taken into account in future economic evaluations.
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OBJECTIVES: Chronic inflammation in rheumatoid arthritis (RA) may interfere
with bone remodelling. Small studies have suggested biologic DMARDs preserve
bone mineral density at 6-12 months. Our objective was to determine the risk of
non-vertebral osteoporotic fractures in RA subjects aged50, comparing outcomes
in patients who were exposed or unexposed to biologic DMARDs. METHODS: A
nested case-control study from January 2002 to December 2008 was conducted
using Quebec physician billing and hospital discharge data. RA subjects were iden-
tified from ICD-9/10 codes in billing and hospitalization data. Subjects were fol-
lowed until the earliest of non-vertebral osteoporotic fracture (index date), death,
or end of study period. A validated algorithm identified non-vertebral osteoporotic
fractures from physician claims. Controls were matched to cases (4:1 ratio) on age,
sex, and date of study entry. Biologic DMARD exposure was defined as being on
treatment for 180 days pre-index. Conditional logistic regression was used, ad-
justing for indicators of RA severity, comorbidity, drugs influencing fracture risk,
and measures of health care utilization. RESULTS: Over the study period, 1,803
cases were identified (7,175 controls). The most frequent fracture site was hip/
femur (43.7%). In total, 190 subjects (53 cases, 137 controls) were exposed to biologic
DMARDs. We were unable to demonstrate an association between biologic
DMARDs and fracture risk (Odds Ratio, OR [95% Confidence Interval, CI]: 1.16 [0.51-
2.62]). RA duration had the strongest impact on fracture risk; for subjects of RA
duration10 years (vs.5), the OR was 6.40 (95% CI 3.57-11.46), while those with RA
duration 5-10 years (vs. 5) had an OR of 3.05 (95%CI 1.90-4.89). The inability to
detect an effect remained in sensitivity analyses. CONCLUSIONS: Despite the pos-
itive impact of biologic DMARDs on bone remodelling observed in small studies, we
were unable to demonstrate a reduction in the risk of non-vertebral osteoporotic
fractures in older adults with RA.
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OBJECTIVES: In Italy the epidemiological data and the Dupuytren disease care
practice description are poor and come mainly from extrapolation of data obtained
in other countries. The objective of this study was to assess the prevalence and the
management of this disease in Italy and in the Italian regions. METHODS: Data
have been obtained from CSD LPD General Practitioner’s (GPs) longitudinal data-
base. Patients with at least one diagnosis of Dupuytren disease between October
2008 and September 2010 were selected. Patients were followed-up for 12 months
since the First Diagnosis date. Study results have been stratified by macro areas.
RESULTS: 1.829 patients (62,55% men, 37,45% women) with at least one diagnosis of
Dupuytren disease have been selected. Disease prevalence was estimated at 0,15%
patients nationwide and at 0.178% , 0.229%, 0.123% ,0.082% patients in the Nord-
West, Nord-East, Center and South-Islands respectively. Prevalence increased with
age: 35% of the patients were aged over 65 y. Only 32 % of the patients benefited
from a specialist visit request for the Dupuytren disease during the follow-up pe-
riod; 70,7% of those requests were for orthopedic visits, 13,5% for hand surgery and
7,5% for physiatry. Macro area analysis showed some differences in the specialists
visits distribution. CONCLUSIONS: The prevalence analysis showed a slight differ-
ence among macro areas underlining a major prevalence of the disease in the
Nord-East compared to the South–Islands area. The prevalence of the disease in the
CSD LPD database in Italy was of 0.15% which is significantly lower than that
reported in the literature. This is probably due to the fact that the majority of
Dupuytren published studies were conducted in Nordic countries where the dis-
ease is mainly diffused. Also, the data collection methods and the age groups could
be different, and, further, many researches were carried out in a specialist setting
only.
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OBJECTIVES: To model the annual impact on hospital costs following the introduc-
tion of sugammadex for routine reversal of neuromuscular blockade. METHODS:
An economic model reflecting resource use and costs associated with neuromus-
cular block and its reversal, and residual blockade, was constructed for a typical
Greek hospital. Clinical trial data were used to estimate time savings relating to
shortened reversal in the operating room (OR) for sugammadex compared to
neostigmine and no reversal. Costs of OR time were derived from labor costs for
different types of OR staff. Resource use associated with residual blockade sequelae
(aspiration, hypoxemia, muscle weakness, upper airway obstruction) was esti-
mated from the literature. Annual procedures, utilization of neuromuscular block-
ing and reversal agents, and uptake of sugammadex within a typical Greek hospital
were estimated. Unit costs were based on public data sources or published
literature. RESULTS: If all OR staff modeled (with average staff attendance across
all procedures of 2.4 anesthetists, 3.5 surgeons and 3.7 nurses) can realize time
savings with shortened reversal, use of sugammadex is estimated to save a typical
Greek hospital, using sugammadex in 7,130 procedures annually, 23,717 € per year.
This corresponds to an increase in drug costs of 358,963 €, which is more than fully
offset by a decrease in costs of OR staff and clinical sequelae of residual blockade
(-382,680 €). In a worst case scenario, if only one second degree anesthetist, one
second degree surgeon and one nurse in attendance realize time savings, annual
costs would be increased (198,404 €). Results were sensitive to OR staff costs and
time savings. CONCLUSIONS: Sugammadex for routine reversal of neuromuscular
blockade can potentially lead to cost savings in the Greek health care setting. The
degree to which costs may be saved depends upon which OR staff can realize time
savings with shortened reversal.
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OBJECTIVES: To assess differences in treatment costs for patients with anti-TNFs
for ankylosing spondylitis (AS) and rheumatoid arthritis (RA), according to their
route of administration. METHODS: A budget impact analysis was designed to
study the costs of each administration route, whether administered subcutane-
ously (SC) in the ambulatory setting or administered intravenously (IV) in an out-
patient hospital setting, from the perspective of the French Statutory Health Insur-
ance. Costs and tariffs are official statutory tariffs. The dosages of each treatment
stem from the Summary of Product Characteristics. Costs were followed-up over 2
years (induction  maintenance). For the weight, a gold standard of 70 kg was
considered. Scenarios were modeled for cohorts of 100 patients. Costs for nurse
have been systematically taken into account for each SC injection associated to a
specialist consultation every 3 months. Initially for IV drugs no ambulatory addi-
tional costs and no transportation costs were considered. RESULTS: For AS, the
average cost for SC drugs over 2 years was 23 471€ while it was 31 086€ for infusion
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